LSPA: Unifying Pennsylvania’s Life Sciences Ecosystem
A conversation with Christopher Molineaux, President & CEO of Life Sciences Pennsylvania, on advocacy, innovation, and what it takes to make a state a global life sciences leader.
Life Sciences Pennsylvania (LSPA) has been the statewide trade association for Pennsylvania’s life sciences industry since 1989. With more than 960 member organizations — spanning biotech, pharma, medical devices, diagnostics, research institutions, and investors — LSPA serves as both the political voice and connective tissue for one of the nation’s most dynamic life sciences ecosystems.
In this Spotlight, President & CEO Christopher Molineaux discusses how LSPA distinguishes itself through deep policy expertise and a uniquely broad network, highlights recent federal advocacy wins that matter for innovators nationwide, and shares where the industry’s attention is turning — from artificial intelligence to the reshoring of clinical trials.
The Spotlight
Q1. What does Life Sciences Pennsylvania do, and who do you serve?
Life Sciences Pennsylvania is the statewide trade association for Pennsylvania’s life sciences industry. Our mission is to ensure Pennsylvania is a life sciences leader by facilitating the formation, growth, and success of the ecosystem through public policy advocacy and by connecting people, organizations, and resources across the Commonwealth.
Q2. What sets Life Sciences Pennsylvania apart from others in your space?
LSPA is dedicated to public policy advocacy — serving as the voice for more than 960 member organizations across Pennsylvania and beyond that are committed to advancing patient care, improving global health, and driving the economic growth of the Commonwealth. Our network is among the strongest of any state life sciences association in the nation, spanning companies statewide alongside legislators and state and federal policymakers.
Our team is led by an industry veteran with more than 35 years of experience in public policy, strategic communications, and board-level service at publicly traded and private biotech, specialty pharma, and diagnostic companies. That depth of experience — at the intersection of policy and industry — gives LSPA a distinctive understanding of the challenges and opportunities that life sciences companies face at every stage of development.
Q3. What is a recent result you’re particularly proud of?
In early February 2026, the Rare Pediatric Disease Priority Review Voucher (PRV) Program was fully funded through September 30, 2029. The program had lapsed in December 2024 despite strong bipartisan support, halting a critical incentive for developers of novel treatments for rare pediatric diseases — and its restoration was a significant win for the patient community and for industry.
Equally significant was the passage of the Small Business Innovation and Economic Security Act in the U.S. Senate on March 3, 2026, followed quickly by the House, reauthorizing the SBIR and STTR programs through September 30, 2031. The reauthorization ended a five-month lapse that had halted new awards and created widespread uncertainty across the life sciences ecosystem. In 2024 alone, Pennsylvania companies received 226 SBIR/STTR awards totaling nearly $134 million. Throughout 2025, Life Sciences Pennsylvania led a statewide advocacy effort in support of reauthorization and helped secure strong bipartisan backing from Pennsylvania’s congressional delegation.
Q4. Which regions do you serve, and where are you especially focused?
Pennsylvania — including the Philadelphia region, which is part of Big4Bio’s coverage area — is our primary focus. That said, Life Sciences Pennsylvania is not geographically bound. Our membership includes more than 120 organizations headquartered outside the Commonwealth, among them companies based in Cambridge and Boston, San Francisco, San Diego, New York City, and the Capital Region. Our policy work and advocacy often have national implications, which means our reach extends well beyond state lines.
Q5. What trend or challenge are your members asking about most right now?
Two themes come up consistently. The first is artificial intelligence: member organizations are actively exploring how AI can accelerate research, help identify novel targets, and support regulatory compliance. The second is the reshoring of clinical trials — specifically, how to develop regulatory and policy frameworks that make Pennsylvania, and the U.S. more broadly, more competitive with overseas geographies for investigator-initiated trials and clinical research generally.
As members navigate both of these shifts, Life Sciences Pennsylvania continues to serve as a trusted resource and advocate. We work to ensure that policymakers understand the real-world impact of these challenges, while giving our members the education, connections, and insights they need to make informed decisions and grow their organizations.
About The Organization
Life Sciences Pennsylvania
Life Sciences Pennsylvania is the statewide trade association for Pennsylvania’s life sciences industry. Founded in 1989, LSPA’s mission is to make Pennsylvania a life sciences leader by facilitating the formation, growth, and success of the ecosystem through public policy advocacy and by connecting people and resources. Its membership represents the full breadth of the industry — research institutions, biotechnology, medical device, diagnostic, pharmaceutical, and investment organizations, along with the service providers that support them. Together, LSPA unifies Pennsylvania’s innovators in pursuit of making the Commonwealth a global life sciences leader.